| 6.68 | 0.15 | 2.30% | 169,645 | Market data is delayed by at least 20 minutes. | ||
| Last | Change | / | % Change | Volume |
|
Exclusive Features |
||
| When you open a Scottrade account, you will be able to trade, add stocks to a watch list, set alerts and get real-time quotes. | Or | |
|
--/--
Bid/Size |
--/--
Ask/Size |
6.30
Price Open |
||
|
6.53
Previous Close |
6.81
Day High |
6.20
Day Low |
||
|
--
Beta (5yr) |
15.88/5/28/08
52wk High/Date |
4.41/10/29/08
52wk Low/Date |
||
|
417.5 Million
Market Capitalization |
62.5 Million
Shares Outstanding |
95.70
Volatility Avg (20 day) |
||
|
128.6 Thousand
Avg Vol (10 day) |
8.9x
P/E Ratio |
0.75
EPS (TTM) |
||
|
Simcere Pharmaceutical Group does not pay dividends. |
||||
Get the following exclusive content at no additional cost with your Scottrade account:
- Standard & Poor's STARS Rating for the featured stock
- Research reports from Reuters and Standard & Poor's
- Market Edge Second Opinion Weekly Report
Company Background
Simcere Pharmaceutical Group (Simcere Pharmaceutical) is a manufacturer and supplier of branded generic pharmaceuticals in the Chinese market. Its focus is to introduce generic and pharmaceutical products for the treatment of diseases with high incidence and/or mortality rate. The Company has introduced a generic anti-stroke medication under the brand name, Bicun, and an anti-cancer medication under the brand name, Endu. Its products include antibiotics, anti-stroke medications, anti-inflammatory drugs, anti-cancer medications and other medicines. In addition, it has obtained approvals from the China State Food and Drug Administration (SFDA) to manufacture and sell over 210 other products. In November 2007, the Company acquired Master Luck Corporation Limited, which holds 85.7% of Nanjing Tung Chit Pharmaceutical Co., Ltd.
Brokerage Products and Services offered by Scottrade, Inc. - Member FINRA and SIPC
Any specific securities, or types of securities, used as examples are for demonstration purposes only. No information on this Web site should be considered a recommendation or solicitation to invest in, or liquidate, a particular security or type of security.
Investors should consider the investment objectives, risks, and charges and expenses of a mutual fund carefully before investing. A mutual fund's prospectus contains this and other information about the mutual fund. Prospectuses are available through our trading site or through a Scottrade branch office. The prospectus should be read carefully before investing. No transaction fee (NTF) funds are subject to the terms and conditions of the NTF funds program. Scottrade is compensated by the funds participating in the NTF program through recordkeeping, shareholder, or SEC 12b-1 fees.
Investors should consider the investment objectives, risks, charges, and expenses of an Exchange-Traded Fund (ETF) carefully before investing. A prospectus contains this and other information about the ETF can be obtained from the issuer. The prospectus should be read carefully before investing.
Margin trading involves interest charges and risks, including the potential to lose more than deposited, or the need to deposit additional collateral in a falling market. Margin Disclosure Statement (PDF) is available for download, or it is available at one of our branch offices. It contains information on our lending policies, interest charges, and the risks associated with margin accounts.
Options are not appropriate for all investors. Detailed information on our policies and the risks associated with options can be found in Scottrade's Options Application and Agreement, Brokerage Account Agreement, and Characteristics and Risks of Standardized Options (also available at one of our branch offices). All option accounts require prior approval by Scottrade.
Online market and limit equity orders are just $7 for stocks over $1.
Market volatility, volume, and system availability may impact account access and trade execution.
Testimonials may not be representative of the experience of other clients and are no guarantee of future performance or success.